期刊文献+

贞清胶囊的水提醇沉工艺探讨 被引量:2

Study on the process of extraction and purification for Zhenqing Capsules
原文传递
导出
摘要 目的:筛选贞清胶囊的水提醇沉最佳工艺条件。方法:高效液相色谱法测定水煎液和醇沉液中马钱苷的含量;以马钱苷提取率和干膏率为评价指标,采用正交设计法考察加水量、水提时间、水提次数等因素对水提工艺的影响;考察醇沉前药液相对密度、醇沉浓度、醇沉时间三因素对醇沉工艺的影响。结果:最佳水提工艺条件为加入8倍量水,提取2次,每次1.5h(100℃);最佳醇沉工艺条件即加入乙醇使含醇量达60%,水提液浓缩体积比为1∶1.2,醇沉时间24h。结论:经正交设计筛选贞清胶囊的水提醇沉工艺是科学可行的。 OBJECTIVE To optimize the process of extraction and purification of Zhenqing capsules by orthogonal design. METHODS The contents of loganin of Zhenqing capsules in water solution were detected by HPLC. The content of loganin and rate of dry were determined and taken as the assessment index; the effects of three factors, water volume, extraction time, extraction times on extraction were evaluated by orthogonal design. The effects of another three factors, alcohol volume, concentra tion of condensed solution, reaction time on content of Zhenqing capsules of alcohol precipitation were also evaluated by orthogonal design. RESULTS The optimum water extraction process was as follows: water was used as the extracting solvent, two times of extracting 1.5 h each time,8 times solvent to the decoction pieces (100℃); the best alcohol precipitation process was that 60% of precipitation concentration,concentrated volume ratio of extraction is 1:1.2,alcohol deposit lasted 24 hours. CONCLUSION The water-extraction and alcohol-precipitation process of Zhenqing capsules by orthogonal design is scientific and feasible.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2011年第8期619-621,共3页 Chinese Journal of Hospital Pharmacy
基金 国家自然基金资助项目(编号:30672730)
关键词 正交设计 水提醇沉工艺 马钱苷 orthogonal design the wate-extraction and alcohol precipitation process loganin
  • 相关文献

参考文献2

二级参考文献15

  • 1石珺,文秀英,胡衍园,许明旺,陈斌.复方桑椹对2型糖尿病肾脏病变疗效的实验研究[J].中国中西医结合杂志,2003,23(S1):131-133. 被引量:7
  • 2胡衍园,文秀英,石珺,许明望.五龙克糖口服液对2型糖尿病大鼠胰岛β细胞的保护作用[J].中国中西医结合杂志,2003,23(S1):123-126. 被引量:4
  • 3杨小清,黄俭,李钊成.调脂舒脉方治疗高脂血症气阴两虚证40例疗效观察[J].新中医,2004,36(9):22-23. 被引量:1
  • 4Lin J, Hu F B, Rimm E B, et al. The association of serum lipids and inflammatory biomarkers with renal function in men with type Ⅱ diabetes mellitus [ J ]. Kidney Int,2006,69(2) : 206 -208. 被引量:1
  • 5Aso Y, Matsumoto S, Fujiwara Y, et al. Impaired fibrinolytic for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1 [J]. Metabolism,2002,51 (4) : 471 -476. 被引量:1
  • 6Zhuo W W, Tao J, Jin P L. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVB^db/db mice with type 2 diabetes[J]. Diabetes,2005,54:2328 - 2335. 被引量:1
  • 7Mogensen C E. Managemant of early nephropathy in diabetic patients[J]. Annu Rev Med ,1995 , 46 : 79. 被引量:1
  • 8Ruan X Z, Varghese Z, Powis S H, et al. Dysregulation of LDL recaptor under the influence of inflamematory cytokines: A new pathway for foam cell formation [ J ].Kidney Int,2001,60(5) : 1716 -1725. 被引量:1
  • 9Martinez C A, Ramo R, Gonzalez M T, et al. Dyslipidemia and cardiovascular risk in type 2 diabetes mellitus patients with associated diabetic nephropathy[J]. Nefrologia,2002,22(Suppl):51 - 58. 被引量:1
  • 10Gotz A K, Boger C A, Hirschmann C, et al. Effect of HMG-CoA-reductase inhibitors on survival in type 2 diabetes patients with end stage diabetic nephropathy[ J]. Eur J Med Res,2005,20,10(4):155 - 160. 被引量:1

共引文献18

同被引文献24

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部